WO2002020758A3 - Nouvelles proteines et acides nucleiques codant pour ces proteines - Google Patents

Nouvelles proteines et acides nucleiques codant pour ces proteines Download PDF

Info

Publication number
WO2002020758A3
WO2002020758A3 PCT/US2001/027435 US0127435W WO0220758A3 WO 2002020758 A3 WO2002020758 A3 WO 2002020758A3 US 0127435 W US0127435 W US 0127435W WO 0220758 A3 WO0220758 A3 WO 0220758A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
acids encoding
encoding same
novel proteins
disclosed
Prior art date
Application number
PCT/US2001/027435
Other languages
English (en)
Other versions
WO2002020758A2 (fr
Inventor
Muralidhara Padigaru
Esha A Gangolli
Suresh Shenoy
Valerie L Gerlach
John Macdougall
Glennda Smithson
David Stone
Karen Ellerman
Original Assignee
Curagen Corp
Muralidhara Padigaru
Esha A Gangolli
Suresh Shenoy
Valerie L Gerlach
John Macdougall
Glennda Smithson
David Stone
Karen Ellerman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Muralidhara Padigaru, Esha A Gangolli, Suresh Shenoy, Valerie L Gerlach, John Macdougall, Glennda Smithson, David Stone, Karen Ellerman filed Critical Curagen Corp
Priority to AU2001290613A priority Critical patent/AU2001290613A1/en
Publication of WO2002020758A2 publication Critical patent/WO2002020758A2/fr
Publication of WO2002020758A3 publication Critical patent/WO2002020758A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des séquences d'acide nucléique codant pour de nouveaux polypeptides. L'invention concerne également des polypeptides codés par ces séquences d'acide nucléique, et des anticorps, qui se lient de manière immunospécifique à ce polypeptide, ainsi que des dérivés, des variants, des mutants, ou des fragments du polypeptide, du polynucléotide ou de l'anticorps susmentionnés. L'invention concerne également des procédés thérapeutiques, de diagnostic et de recherche, pour le diagnostic, le traitement et la prévention de troubles impliquant un de ces nouveaux acides nucléiques et protéines humains.
PCT/US2001/027435 2000-09-05 2001-09-05 Nouvelles proteines et acides nucleiques codant pour ces proteines WO2002020758A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001290613A AU2001290613A1 (en) 2000-09-05 2001-09-05 Novel proteins and nucleic acids encoding same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22999800P 2000-09-05 2000-09-05
US22999000P 2000-09-05 2000-09-05
US60/229,988 2000-09-05
US60/229,990 2000-09-05

Publications (2)

Publication Number Publication Date
WO2002020758A2 WO2002020758A2 (fr) 2002-03-14
WO2002020758A3 true WO2002020758A3 (fr) 2003-06-12

Family

ID=26923812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027435 WO2002020758A2 (fr) 2000-09-05 2001-09-05 Nouvelles proteines et acides nucleiques codant pour ces proteines

Country Status (1)

Country Link
WO (1) WO2002020758A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5198848B2 (ja) * 2004-03-29 2013-05-15 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ マクロファージ遊走阻止因子阻害剤を用いる、１型糖尿病処置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031468A1 (fr) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Facteur-3 inhibiteur de la migration des macrophages
US5650295A (en) * 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6043044A (en) * 1997-07-15 2000-03-28 Hudson; Perry B. Macrophage migration inhibitory factor as diagnostic and prognostic marker for metastatic adenocarcinoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031468A1 (fr) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Facteur-3 inhibiteur de la migration des macrophages
US5650295A (en) * 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6043044A (en) * 1997-07-15 2000-03-28 Hudson; Perry B. Macrophage migration inhibitory factor as diagnostic and prognostic marker for metastatic adenocarcinoma

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 15 June 1996 (1996-06-15), FITZGERALD, XP002219996, Database accession no. AAR83048 *
DATABASE EMBL 28 June 1996 (1996-06-28), THELIN S. ET AL.: "Human D-dopachrome tautomerase mRNA", XP002220301, Database accession no. U49785 *
FINGERLE-ROWSON GUNTER R ET AL: "Neuroendocrine properties of macrophage migration inhibitory factor (MIF).", IMMUNOLOGY AND CELL BIOLOGY, vol. 79, no. 4, August 2001 (2001-08-01), pages 368 - 375, XP002220298, ISSN: 0818-9641 *
HUDSON J D ET AL: "PROINFLAMMATORY CYTOKINE INHIBITS P53 TUMOR SUPPRESSOR ACTIVITY", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 190, no. 10, November 1999 (1999-11-01), pages 1375 - 1382, XP000882506, ISSN: 0022-1007 *
MARKERT JAMES M ET AL: "Differential gene expression profiling in human brain tumors.", PHYSIOLOGICAL GENOMICS, vol. 5, June 2001 (2001-06-01), June, 2001, pages 21 - 33, XP002220299, ISSN: 1094-8341 *
MITCHELL ROBERT A ET AL: "Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF).", SEMINARS IN CANCER BIOLOGY, vol. 10, no. 5, October 2000 (2000-10-01), pages 359 - 366, XP002220300, ISSN: 1044-579X *

Also Published As

Publication number Publication date
WO2002020758A2 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
WO2002014368A8 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002006339A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2002055705A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2002064791A3 (fr) Proteines et acides nucleiques codant celles-ci
WO2002050277A3 (fr) Proteines et acides nucleiques codant pour celles-ci
WO2002068649A3 (fr) Proteines et acides nucleiques les codant
WO2002057453A3 (fr) Polypeptides et acides nucleiques codant ces derniers
WO2002057450A3 (fr) Proteines et acides nucleiques les codant
WO2002081518A3 (fr) Proteines, polynucleotides les codant et leurs procedes d'utilisation
WO2001060990A3 (fr) Nouvelles kinases de sphingosine
WO2001090155A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002029058A3 (fr) Nouvelles proteines humaines, polynucleotides codant pour ces proteines et methodes d'utilisation associees
WO2002098917A3 (fr) Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
WO2002068652A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2001081578A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2004015060A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation associees
WO2002016599A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2002029038A3 (fr) Nouvelles proteines, acides nucleiques codant ces derniers et anticorps diriges contre ces proteines
WO2002055704A3 (fr) Proteines, polynucleotides codant pour elles et procedes d'utilisation correspondants
WO2002010216A3 (fr) Nouvelles proteines et acides nucleiques codant pour elles
WO2002055702A3 (fr) Protéines humaines, polynucléotides les codant et procédés d'utilisation correspondants
WO2002081510A3 (fr) Proteines, polynucleotides codant pour celles-ci et methodes d'utilisation
WO2002046229A3 (fr) Nouvelles proteines et acides nucleiques codant celles-ci
WO2002066643A3 (fr) Proteines, polynucleotides codant pour ces proteines et procedes d'utilisation
WO2001066747A8 (fr) Nouvelles proteines et acides nucleiques codant lesdites proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP